Literature DB >> 25853696

Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling.

Nils P Nickel1, Edda Spiekerkoetter, Mingxia Gu, Caiyun G Li, Hai Li, Mark Kaschwich, Isabel Diebold, Jan K Hennigs, Ki-Yoon Kim, Kazuya Miyagawa, Lingli Wang, Aiqin Cao, Silin Sa, Xinguo Jiang, Raymond W Stockstill, Mark R Nicolls, Roham T Zamanian, Richard D Bland, Marlene Rabinovitch.   

Abstract

RATIONALE: Pulmonary arterial hypertension is characterized by endothelial dysfunction, impaired bone morphogenetic protein receptor 2 (BMPR2) signaling, and increased elastase activity. Synthetic elastase inhibitors reverse experimental pulmonary hypertension but cause hepatotoxicity in clinical studies. The endogenous elastase inhibitor elafin attenuates hypoxic pulmonary hypertension in mice, but its potential to improve endothelial function and BMPR2 signaling, and to reverse severe experimental pulmonary hypertension or vascular pathology in the human disease was unknown.
OBJECTIVES: To assess elafin-mediated regression of pulmonary vascular pathology in rats and in lung explants from patients with pulmonary hypertension. To determine if elafin amplifies BMPR2 signaling in pulmonary artery endothelial cells and to elucidate the underlying mechanism.
METHODS: Rats with pulmonary hypertension induced by vascular endothelial growth factor receptor blockade and hypoxia (Sugen/hypoxia) as well as lung organ cultures from patients with pulmonary hypertension were used to assess elafin-mediated reversibility of pulmonary vascular disease. Pulmonary arterial endothelial cells from patients and control subjects were used to determine the efficacy and mechanism of elafin-mediated BMPR2 signaling.
MEASUREMENTS AND MAIN RESULTS: In Sugen/hypoxia rats, elafin reduced elastase activity and reversed pulmonary hypertension, judged by regression of right ventricular systolic pressure and hypertrophy and pulmonary artery occlusive changes. Elafin improved endothelial function by increasing apelin, a BMPR2 target. Elafin induced apoptosis in human pulmonary arterial smooth muscle cells and decreased neointimal lesions in lung organ culture. In normal and patient pulmonary artery endothelial cells, elafin promoted angiogenesis by increasing pSMAD-dependent and -independent BMPR2 signaling. This was linked mechanistically to augmented interaction of BMPR2 with caveolin-1 via elafin-mediated stabilization of endothelial surface caveolin-1.
CONCLUSIONS: Elafin reverses obliterative changes in pulmonary arteries via elastase inhibition and caveolin-1-dependent amplification of BMPR2 signaling.

Entities:  

Keywords:  apelin; arterial smooth muscle cells; endothelial cell apoptosis; neutrophil elastase inhibition; pulmonary vascular regeneration and angiogenesis

Mesh:

Substances:

Year:  2015        PMID: 25853696      PMCID: PMC4476518          DOI: 10.1164/rccm.201412-2291OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  50 in total

1.  Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension.

Authors:  Suparna M Chandra; Hedi Razavi; Jongmin Kim; Rani Agrawal; Ramendra K Kundu; Vinicio de Jesus Perez; Roham T Zamanian; Thomas Quertermous; Hyung J Chun
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-01-13       Impact factor: 8.311

2.  Exogenous leukocyte and endogenous elastases can mediate mitogenic activity in pulmonary artery smooth muscle cells by release of extracellular-matrix bound basic fibroblast growth factor.

Authors:  K Thompson; M Rabinovitch
Journal:  J Cell Physiol       Date:  1996-03       Impact factor: 6.384

3.  Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival.

Authors:  Tero-Pekka Alastalo; Molong Li; Vinicio de Jesus Perez; David Pham; Hirofumi Sawada; Jordon K Wang; Minna Koskenvuo; Lingli Wang; Bruce A Freeman; Howard Y Chang; Marlene Rabinovitch
Journal:  J Clin Invest       Date:  2011-08-08       Impact factor: 14.808

4.  Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension.

Authors:  Syed H E Zaidi; Xiao-Mang You; Sorana Ciura; Mansoor Husain; Marlene Rabinovitch
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

5.  The antimicrobial/elastase inhibitor elafin regulates lung dendritic cells and adaptive immunity.

Authors:  Ali Roghanian; Steven E Williams; Tara A Sheldrake; Tom I Brown; Karen Oberheim; Zhou Xing; Sarah E M Howie; Jean-Michel Sallenave
Journal:  Am J Respir Cell Mol Biol       Date:  2006-01-19       Impact factor: 6.914

6.  Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor.

Authors:  Carl Atkinson; Susan Stewart; Paul D Upton; Rajiv Machado; Jennifer R Thomson; Richard C Trembath; Nicholas W Morrell
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

7.  Elafin, a serine elastase inhibitor, attenuates post-cardiac transplant coronary arteriopathy and reduces myocardial necrosis in rabbits afer heterotopic cardiac transplantation.

Authors:  B Cowan; O Baron; J Crack; C Coulber; G J Wilson; M Rabinovitch
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

8.  Temporal hemodynamic and histological progression in Sugen5416/hypoxia/normoxia-exposed pulmonary arterial hypertensive rats.

Authors:  Michie Toba; Abdallah Alzoubi; Kealan D O'Neill; Salina Gairhe; Yuri Matsumoto; Kaori Oshima; Kohtaro Abe; Masahiko Oka; Ivan F McMurtry
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-11-15       Impact factor: 4.733

9.  Caveolae, caveolins, cavins, and endothelial cell function: new insights.

Authors:  Grzegorz Sowa
Journal:  Front Physiol       Date:  2012-01-06       Impact factor: 4.566

10.  Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the alpha v beta 3 integrin to promote epidermal growth factor receptor phosphorylation and growth.

Authors:  P L Jones; J Crack; M Rabinovitch
Journal:  J Cell Biol       Date:  1997-10-06       Impact factor: 10.539

View more
  69 in total

1.  Matrix Remodeling Promotes Pulmonary Hypertension through Feedback Mechanoactivation of the YAP/TAZ-miR-130/301 Circuit.

Authors:  Thomas Bertero; Katherine A Cottrill; Yu Lu; Christina M Haeger; Paul Dieffenbach; Sofia Annis; Andrew Hale; Balkrishen Bhat; Vivek Kaimal; Ying-Yi Zhang; Brian B Graham; Rahul Kumar; Rajan Saggar; Rajeev Saggar; W Dean Wallace; David J Ross; Stephen M Black; Sohrab Fratz; Jeffrey R Fineman; Sara O Vargas; Kathleen J Haley; Aaron B Waxman; B Nelson Chau; Laura E Fredenburgh; Stephen Y Chan
Journal:  Cell Rep       Date:  2015-10-22       Impact factor: 9.423

2.  Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-β in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension.

Authors:  Nancy F Tojais; Aiqin Cao; Ying-Ju Lai; Lingli Wang; Pin-I Chen; Miguel A Alejandre Alcazar; Vinicio A de Jesus Perez; Rachel K Hopper; Christopher J Rhodes; Matthew A Bill; Lynn Y Sakai; Marlene Rabinovitch
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-06-15       Impact factor: 8.311

Review 3.  New and Emerging Therapies for Pulmonary Arterial Hypertension.

Authors:  Edda Spiekerkoetter; Steven M Kawut; Vinicio A de Jesus Perez
Journal:  Annu Rev Med       Date:  2018-09-14       Impact factor: 13.739

Review 4.  Inflammation in Pulmonary Arterial Hypertension.

Authors:  Timothy Klouda; Ke Yuan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Elafin in pulmonary arterial hypertension. Beyond targeting elastases.

Authors:  Hyung J Chun; Paul B Yu
Journal:  Am J Respir Crit Care Med       Date:  2015-06-01       Impact factor: 21.405

6.  Patient-Specific iPSC-Derived Endothelial Cells Uncover Pathways that Protect against Pulmonary Hypertension in BMPR2 Mutation Carriers.

Authors:  Mingxia Gu; Ning-Yi Shao; Silin Sa; Dan Li; Vittavat Termglinchan; Mohamed Ameen; Ioannis Karakikes; Gustavo Sosa; Fabian Grubert; Jaecheol Lee; Aiqin Cao; Shalina Taylor; Yu Ma; Zhixin Zhao; James Chappell; Rizwan Hamid; Eric D Austin; Joseph D Gold; Joseph C Wu; Michael P Snyder; Marlene Rabinovitch
Journal:  Cell Stem Cell       Date:  2016-12-22       Impact factor: 24.633

7.  Induced Pluripotent Stem Cells in Pulmonary Arterial Hypertension.

Authors:  Rizwan Hamid; Ling Yan
Journal:  Am J Respir Crit Care Med       Date:  2017-04-01       Impact factor: 21.405

8.  Arterial stiffness induces remodeling phenotypes in pulmonary artery smooth muscle cells via YAP/TAZ-mediated repression of cyclooxygenase-2.

Authors:  Paul B Dieffenbach; Christina Mallarino Haeger; Anna Maria F Coronata; Kyoung Moo Choi; Xaralabos Varelas; Daniel J Tschumperlin; Laura E Fredenburgh
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-06-22       Impact factor: 5.464

9.  Shared gene expression patterns in mesenchymal progenitors derived from lung and epidermis in pulmonary arterial hypertension: identifying key pathways in pulmonary vascular disease.

Authors:  Christa Gaskill; Shennea Marriott; Sidd Pratap; Swapna Menon; Lora K Hedges; Joshua P Fessel; Jonathan A Kropski; DeWayne Ames; Lisa Wheeler; James E Loyd; Anna R Hemnes; Dennis R Roop; Dwight J Klemm; Eric D Austin; Susan M Majka
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

Review 10.  Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies.

Authors:  Monika Spaczyńska; Susana F Rocha; Eduardo Oliver
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.